POSTDOCTORAL RESEARCH TRAINING IN CANCER IMMUNOLOGY

描述（由申请人提供）：过去几年一直是非凡的科学成就和癌症研究扩展的时期，无论是在丹娜-法伯癌症研究所（DFCI）和哈佛医学院社区。 虽然在癌症的诊断和治疗方面取得了重大进展，但这种疾病仍然是儿童和成人死亡的主要原因。 我们对免疫应答的基本理解的重要进展为白血病和实体瘤的诊断和治疗提出了新的临床方法。 在基础生物科学领域，包括肿瘤抑制基因、细胞周期调控、癌基因信号传导、细胞分化、细胞凋亡控制、器官发生和血管生成，都取得了重大进展。 靶向癌症治疗的最新进展，癌细胞成像的新模式，以及对遗传学和癌症风险的更深入了解，突出了这些发现转化研究的潜力，反过来，为今天的年轻科学家开辟了新的机会领域。 这项工作的一个重要组成部分是培训基础和临床免疫学的年轻科学家，使他们成为癌症免疫学的独立研究人员。 在DFCI，转化研究多年来一直是基础和临床免疫学教师之间的持续合作。 最近成立的丹娜-法伯/哈佛癌症中心，一个联盟的附属医院，使我们的培训教师扩大，包括来自整个哈佛医学院社区的杰出科学家，所有这些人都是在基础和转化/临床免疫学的领先研究者。 此外，基础设施和核心资源的扩大增加了获得试剂的机会，并为开展研究提供了更有效的框架。 该计划将继续由哈维·康托尔博士指导，他与培训计划小组委员会一起负责候选人的选择，计划课程，学员研究的年度审查以及促进学生和教师之间的互动。 该计划的长期目标是培养基础科学家在癌症免疫学方面进行独立的高质量研究。

DESCRIPTION (provided by applicant): The last several years have been a period of extraordinary scientific achievement and cancer research expansion, both at Dana-Farber Cancer Institute (DFCI) and within the Harvard Medical School community. Although significant progress has been made in the diagnosis and treatment of cancer, this disease continues to represent a major cause of childhood and adult mortality. Important advances in our fundamental understanding of the immune response have suggested new clinical approaches to the diagnosis and treatment of leukemias and solid tumors. Significant advances have occurred in the areas of basic biological science, including tumor suppressor genes, cell cycle regulation, oncogene signaling, cell differentiation, apoptosis control, organogenesis and angiogenesis. Recent advances in targeted cancer therapies, new modalities of cancer cell imaging, and a deeper understanding of genetics and cancer risk highlight the potential of these discoveries to translational research which, in turn, has opened new areas of opportunity for today's young scientists. An essential part of this effort is the training of young scientists in basic and clinical immunology to become independent investigators in cancer immunology. At DFCI, translational research has been an ongoing collaborative effort between faculty in basic and clinical Immunology for many years. Recent formation of the Dana-Farber/Harvard Cancer Center, a consortium of the affiliated hospitals, has allowed expansion of our training faculty to include distinguished scientists from the entire Harvard Medical School community, all of whom are leading investigators in basic and translational/clinical immunology. In addition, expanded infrastructure and core resources have enhanced access to reagents and provide a more efficient framework in which to carry out research. The program will continue to be directed by Dr. Harvey Cantor who, in conjunction with the Training Program Subcommittee, is responsible for candidate selection, program curriculum, annual review of trainee's research and fostering of interactions among student and faculty members within the Program. The long-range goal of the Program is to train basic scientists to conduct independent high-quality research in cancer immunology.